How does ventricular screening work to diagnose heart failure?

Ventricular Screening for Heart Failure Diagnosis

Ventricular screening for heart failure works through a stepwise algorithm that begins with natriuretic peptide (BNP or NT-proBNP) testing in at-risk patients, followed by echocardiography to assess left ventricular structure and function when biomarker levels are elevated.

The Core Screening Algorithm

The most effective approach combines three key elements in sequence:

Step 1: Identify High-Risk Patients

Target patients with:

• Hypertension
• Diabetes mellitus
• Known vascular disease (coronary artery disease, prior MI)
• Unexplained dyspnea
• Atrial fibrillation
• Obesity

These represent Stage A heart failure patients who warrant screening 1, 2.

Step 2: Natriuretic Peptide Testing

Measure BNP or NT-proBNP as the initial screening tool:

• BNP ≥50 pg/mL triggers further evaluation 1
• NT-proBNP ≥125 pg/mL indicates need for echocardiography 2
• BNP <35 pg/mL or NT-proBNP <125 pg/mL effectively rules out heart failure 2

The STOP-HF trial demonstrated that BNP-based screening in at-risk patients (using a 50 pg/mL cutoff) successfully reduced the composite endpoint of asymptomatic left ventricular dysfunction and newly diagnosed heart failure 1. This represents Class I, Level A evidence supporting biomarker screening.

Step 3: Echocardiographic Assessment

When natriuretic peptides are elevated, echocardiography evaluates:

For HF with Reduced Ejection Fraction (HFrEF):

• Left ventricular ejection fraction (LVEF <40%)
• Regional wall motion abnormalities
• Chamber dimensions

For HF with Preserved Ejection Fraction (HFpEF):

• LVEF ≥50% (or 40-49% for HFmrEF)
• Structural alterations:
  • Left atrial volume index >34 mL/m²
  • LV mass index ≥115 g/m² (males) or ≥95 g/m² (females)
• Functional alterations:
  • E/e′ ≥13
  • Mean e′ (septal and lateral) <9 cm/s
  • Longitudinal strain abnormalities
  • Tricuspid regurgitation velocity 2

Diagnostic Accuracy and Clinical Utility

Natriuretic peptides have higher sensitivity than specificity, making them excellent for ruling out heart failure rather than ruling it in 1. In emergency settings, this characteristic is particularly valuable—a normal level virtually excludes heart failure.

The 2017 ACC/AHA guidelines emphasize that natriuretic peptide testing provides incremental diagnostic value beyond clinical judgment alone, especially when dyspnea etiology is unclear 1.

Important Caveats and Pitfalls

Factors That Elevate Natriuretic Peptides (False Positives):

• Advanced age
• Atrial fibrillation
• Chronic kidney disease
• Pulmonary hypertension
• Acute coronary syndrome
• Sepsis

Factors That Lower Natriuretic Peptides (False Negatives):

• Obesity (most clinically significant—can substantially underestimate filling pressures) 3
• Flash pulmonary edema
• Acute mitral regurgitation

In obese patients with intermediate probability, proceed directly to stress echocardiography or consider invasive hemodynamic testing 3.

Advanced Screening Strategies

Diastolic Stress Testing

When resting echocardiography is inconclusive (particularly in HFpEF):

• Semi-supine bicycle ergometry with echocardiography
• Monitor E/e′ during exercise (>13 is abnormal)
• Assess tricuspid regurgitation velocity
• Evaluate longitudinal strain changes 2

Emerging Technologies

Recent research demonstrates that AI-enabled ECG analysis can detect asymptomatic left ventricular systolic dysfunction with 90.6% sensitivity and 99.4% specificity (AUROC 0.973) 4, though this requires prospective validation before routine clinical use.

Cost-Effective Implementation

A stepwise strategy using symptoms first, then selectively applying NT-proBNP or echocardiography based on clinical context, achieves 100% accuracy with 31.3% cost reduction compared to universal testing 5.

Prognostic Value

Beyond diagnosis, baseline natriuretic peptide levels on hospital admission establish prognosis in acute decompensated heart failure 1. Higher admission levels correlate with increased all-cause mortality, cardiovascular mortality, and morbidity across different time intervals.

The Bottom Line for Clinical Practice

Start with natriuretic peptide testing in any patient with unexplained dyspnea or high-risk features. Use BNP ≥50 pg/mL or NT-proBNP ≥125 pg/mL as your threshold to trigger echocardiography. Remember that obesity significantly reduces natriuretic peptide levels—maintain high clinical suspicion and lower your threshold for echocardiography in obese patients with symptoms. A normal natriuretic peptide level in a non-obese patient effectively excludes heart failure and should redirect your diagnostic workup.